Methods and compositions for promiting glucose homeostasis
AssigneeChildren's Medical Center Corporation
InventorsUmut Ozcan, Jaemin Lee
Life of this patent
Estimating the term…
Loading patent…
AssigneeChildren's Medical Center Corporation
InventorsUmut Ozcan, Jaemin Lee
Estimating the term…
A method of reducing blood glucose in a subject has been developed. In preferred embodiments, the method involves administering to the subject a specific activator of endogenous mitogen-activated protein kinase kinase 6 (MKK3), mitogen-activated protein kinase kinase 6 (MKK4), mitogen-activated protein kinase kinase 6 (MKK6), p38 mitogen-activated protein kinase (p38MAPK), mitogen-activated kinase-activated protein kinase 2 (MK2), or a combination thereof, in an effective amount to reduce blood glucose in a subject. In other embodiments, the method involves administering to the subject a specific activator to increase X-box binding protein 1 (XBP1) phosphorylation on Thr48 and Ser61 in an effective amount to reduce blood glucose in the subject. Methods of identifying agents for reducing blood glucose in a subject are also provided.
1-7. (canceled)
A method of reducing blood glucose in a subject, comprising administering to the subject a pharmaceutical composition comprising a specific activator of X-box binding protein 1 (XBP1) in an effective amount to reduce blood glucose in the subject, wherein the specific activator increases phosphorylation of XBP1 on Thr48 and Ser61.
17-19. (canceled)
Dependencies are inferred from the claim text.